Pooja,
The HbF level is used to tell if hydroxyurea is working. If the drug works, HbF levels should increase as a percentage of the total Hb, and in this case there is hope that the drug will stimulate a higher production of HbF, so that the total Hb also rises. One of the goals of thalassemia management is to decrease the amount of ineffective erythropoiesis in the bone marrow. This is achieved by transfusion in major patients, as the higher the Hb, the less ineffective erythropoiesis that will occur. This ineffective erythropoiesis is what causes the bone marrow to be overactive and cause changes to the bones, weakening them and causing deformities in the bones and skull. So, it is also an important part of managing thal in intermedias. So even if the total Hb percent does not increase, hydroxyurea may be effective in lowering ineffective erythropoiesis, and reducing things like changes to the bone and also spleen size, as the spleen filters out the bad red cells produced in the bone marrow. If the HbF does not show significant change after 6 months and the HbF has not risen, there is less chance of success with the drug. The Hb of the child is still higher than where transfusions would be indicated but the possibility of a continued drop in Hb as she gets older, is a good reason to find out if hydroxyurea can work for her. If it helps to maintain an Hb around 9, she will be able to avoid transfusion. If her Hb continues to drop and her growth and development are affected, transfusions would become necessary.
And one note. Better drugs than hydroxyurea are in development. This will create more options when she is older. The new generation of Hb inducing drugs should have a much greater affect on Hb than hydroxyurea does.